Advisors Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$3.98M Sell
31,689
-5,072
-14% -$638K 0.07% 373
2025
Q1
$4.07M Buy
36,761
+366
+1% +$40.5K 0.08% 345
2024
Q4
$4.97M Sell
36,395
-2,181
-6% -$298K 0.09% 282
2024
Q3
$4.44M Buy
38,576
+4,549
+13% +$524K 0.08% 315
2024
Q2
$4.68M Buy
34,027
+1,386
+4% +$191K 0.09% 282
2024
Q1
$4.5M Buy
32,641
+9,708
+42% +$1.34M 0.09% 292
2023
Q4
$3.02M Buy
22,933
+1,205
+6% +$159K 0.06% 387
2023
Q3
$2.44M Sell
21,728
-6,148
-22% -$692K 0.05% 437
2023
Q2
$2.63M Sell
27,876
-12
-0% -$1.13K 0.05% 429
2023
Q1
$2.82M Buy
27,888
+530
+2% +$53.6K 0.06% 405
2022
Q4
$3.27M Buy
27,358
+5,790
+27% +$692K 0.07% 359
2022
Q3
$2.29M Buy
21,568
+1,361
+7% +$145K 0.05% 456
2022
Q2
$1.97M Buy
20,207
+4,772
+31% +$465K 0.04% 517
2022
Q1
$1.45M Sell
15,435
-3,413
-18% -$320K 0.02% 693
2021
Q4
$1.61M Sell
18,848
-1,222
-6% -$104K 0.02% 682
2021
Q3
$1.93M Sell
20,070
-2,140
-10% -$205K 0.03% 605
2021
Q2
$2.16M Buy
22,210
+998
+5% +$97.1K 0.03% 578
2021
Q1
$2.06M Buy
21,212
+668
+3% +$65K 0.03% 588
2020
Q4
$1.97M Buy
20,544
+2,810
+16% +$269K 0.03% 558
2020
Q3
$1.71M Sell
17,734
-590
-3% -$56.7K 0.03% 524
2020
Q2
$2.24M Buy
18,324
+3,351
+22% +$409K 0.04% 416
2020
Q1
$1.3M Buy
14,973
+2,330
+18% +$202K 0.03% 549
2019
Q4
$1.36M Buy
12,643
+677
+6% +$72.8K 0.02% 659
2019
Q3
$1.08M Buy
11,966
+4,636
+63% +$418K 0.02% 730
2019
Q2
$619K Sell
7,330
-3,170
-30% -$268K 0.01% 936
2019
Q1
$925K Buy
10,500
+336
+3% +$29.6K 0.02% 849
2018
Q4
$726K Buy
10,164
+3,134
+45% +$224K 0.01% 874
2018
Q3
$864K Buy
7,030
+3,628
+107% +$446K 0.01% 884
2018
Q2
$334K Buy
+3,402
New +$334K 0.01% 1146